• 1
    Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997; 111: 17101717.
  • 2
    Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000; 18: 29812989.
  • 3
    Johnson DH, Turrisi AT, Pass HI. Combined modality treatment for locally advanced non-small cell lung cancer. In: PassHI, MitchellJB, JohnsonDH, TurrisiAT, editors. Lung cancer: principles and practice. 2nd ed. New York: Lippincott; 2000: 910920.
  • 4
    Barbacid M. Ras genes. Annu Rev Biochem. 1987; 56: 799827.
  • 5
    Slebos RJC, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990; 323: 561565.
  • 6
    Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994; 330: 153158.
  • 7
    Rodenhuis S, van de Wetering ML, Mooi WJ, et al. Mutational activation of the K-ras oncogene. N Engl J Med. 1987; 317: 929935.
  • 8
    Vachtenheim J, Horáková H, Opálka P, Roubková H. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung. Clin Cancer Res. 1995; 1: 359365.
  • 9
    Cho JY, Kim JH, Lee YH, et al. Correlation between K-ras gene mutation and prognosis of patients with non-small cell lung carcinoma. Cancer. 1997; 79: 462467.
  • 10
    Mills NE, Fishman CL, Rom WN, Dubin N, Jacobson DR. Increased prevalence of k-ras oncogene mutations in lung adenocarcinoma. Cancer Res. 1995; 55: 14441447.
  • 11
    Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992; 10: 243253.
  • 12
    Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Müller KM. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol. 1997;123: 469477.
  • 13
    Thomas M, Rübe C, Semik M, et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol. 1999; 17: 11851193.
  • 14
    Levi S, Urbano-Ispizua A, Gill R, et al. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res. 1991; 51: 34973502.
  • 15
    Syvänen AC. Detection of point mutations in human genes by the solid-phase minisequencing method. Clin Chim Acta. 1994; 226: 225236.
  • 16
    Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 17
    Cox DR. Regression models and life tables [with discussion]. J Royal Stat Soc. 1972; B34: 187–220.
  • 18
    Eberhardt W, Wilke H, Stamatis G, et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: mature results of a phase II trial. J Clin Oncol. 1998; 16: 622634.
  • 19
    Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995; 13: 18801892.
  • 20
    Choi NC, Carey RW, Daly W, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol. 1997; 15: 712722.
  • 21
    Rosell R, Li S, Skacel Z, et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene. 1993; 8: 24072412.
  • 22
    Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K, Sugimachi K. K-ras and p53 mutations are an independent unfavorable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer. 1997; 75: 11251130.
  • 23
    Mitsudomi T, Steinberg SM, Oie HK, Mulshine JL, Phelps R, Viallet J. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res. 1991; 51: 49995002.
  • 24
    Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol. 2001; 19: 448457.
  • 25
    Sklar MD. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science. 1988; 239: 645647.
  • 26
    Sklar MD. Increases resistance to cis-diammine-dichlorpatinum(II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res. 1988; 48: 793797.
  • 27
    Tsai CM, Chang KT, Perng RP, et al. Correlation of intrinsic chemoresistance of non-small cell lung cancer cell lines with HER-2/neu gene expression but not with RAS gene mutations. J Natl Cancer Inst. 1993; 85: 897901.
  • 28
    Rodenhuis S, Boerrigter L, Top B, et al. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol. 1997; 15: 285291.
  • 29
    Thomas M, Rübe C, Semik M, et al. Randomized trial of chemotherapy and twice-daily chemoradiation versus chemotherapy alone before surgery in stage III non-small cell lung cancer. Interim analysis of toxicity [abstract]. Proc Am Soc Clin Oncol. 1999;18: 458a.
  • 30
    Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J. 1995; 311: 899909.
  • 31
    Adjei AA, Erlichman C, Davis JN, et al. A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 2000; 60: 18711877.
  • 32
    Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2000; 18: 927941.